# A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

> **NCT01945086** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 79 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Placebo
- **OTHER:** Concomitant topical medications for atopic dermatitis

## Key facts

- **NCT ID:** NCT01945086
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2016-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945086, "A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01945086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*